Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or C
Explore this paper's citation graph
Summary
The addition of rosiglitazone to SU produced clinically significant improvements in glycemic control in Chinese patients with type 2 diabetes and was well tolerated irrespective of hepatitis B and C serological status.
- Type
- article
- Published
- 2003-01-01
- Cited by
- 24
- References
- 23
- OpenAlex
- https://openalex.org/W2070238084
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23242634
Keywords
Medicine, Rosiglitazone, Gliclazide, Glibenclamide, Sulfonylurea
References
- A novel antidiabetic drug, troglitazone--reason for hope and concern.
- Hepatic dysfunction associated with troglitazone.
- Drug Administration in Patients with Diabetes Mellitus
- Glitazones: Good for Glycemia. Good for the Liver?
- Mortality Risk by Body Weight and Weight Change in People with NIDDM: The WHO Multinational Study of Vascular Disease in Diabetes
- Diabetes--a common, growing, serious, costly, and potentially preventable public health problem.
- Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes
- Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones
- Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones
- Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes.
- Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus
- Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans.
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
- Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
- Improving Management of Type 2 Diabetes Mellitus: 5. Thiazolidinediones
Cited by
- Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus*
- A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
- Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
- A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short‐term, double‐blind, randomized clinical studies with rosiglitazone
- Glitazones: Good for Glycemia. Good for the Liver?
- Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
- Drug Class Review: Thiazolidinediones: Final Report Update 1
- Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH).
- Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
- Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
- Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review.
- Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
- Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c:a meta-analysis of published randomized clinical trials
- Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2
- Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
- Standards of medical care for type 2 diabetes in China 2019
- Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
- Guidelines on primary healthcare for type 2 diabetes in China, 2025
Related papers
- Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly
- Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide.
- THE EFFECTS OF GLICLAZIDE AND GLIBENCLAMIDE ON THE DEVELOPMENT OF ATHEROSCLEROSIS IN A DIABETIC MOUSE MODEL
- A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
- Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
- Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
- Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
- Secondary sulfonylurea failure : comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
- [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].